

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/254690 A1

(51) International Patent Classification:

C12N 5/0783 (2010.01) *C07K 17/00* (2006.01)
A61K 39/00 (2006.01) *C07K 17/08* (2006.01)
A61P 35/00 (2006.01) *C07K 17/14* (2006.01)
A61P 37/04 (2006.01) *C07K 14/725* (2006.01)

(21) International Application Number:

PCT/CA2024/050792

(22) International Filing Date:

12 June 2024 (12.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/472,788 13 June 2023 (13.06.2023) US

(71) Applicant: **NOTCH THERAPEUTICS (CANADA)**

INC. [CA/CA]; 2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA).

(72) Inventors: **CARPENEDO, Richard**; 2233 Columbia

Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA). **CHANDRASEKARAN, Siddarth**; 2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA). **KALATHOTTUKAREN, Manu Thomas**; 2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA). **HOI, Hio Fan**; 2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA). **MARTINEZ, Elisa**; 2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA). **PALLAORO, Alessia**; 2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA). **WOODSIDE, Steven**;

2233 Columbia Street, Suite 300, Vancouver, British Columbia V5Y 0M6 (CA).

(74) Agent: **TORYS LLP**; 79 Wellington Street West, 30th Floor, Toronto, Ontario M5K 1N2 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: STIMULATORY ANTIGEN PARTICLES, METHODS OF PRODUCTION, AND METHODS OF USE THEREOF




FIGURE 25

(57) Abstract: The present disclosure provides cell stimulatory particles and methods of using same. Also provided are populations of cells produced using the cell stimulatory particles.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*